CellRev – Transforming cell culture for a healthier future

The biopharmaceutical industry faces significant challenges in scaling up cell-based therapies and drug manufacturing processes. Traditional methods often encounter bottlenecks such as cell aggregation, clumping, clogging, and detachment, which hinder the efficiency and cost-effectiveness of production. These issues present formidable obstacles to making life-saving treatments more accessible to those in need. CellRev is at the forefront of solving these critical challenges by developing breakthrough solutions for cell culture, enabling the biopharmaceutical industry to overcome the barriers to cost- effective and scalable cell production.

Driving manufacturing efficiency with consistent results

CellRev’s breakthrough technology is centered around an industry-first cell expansion platform that allows for the continuous growth, detachment, and collection of adherent cells—an essential factor for efficient and scalable cell processing. This platform is enhanced by proprietary media additives and custom process development services that ensure consistent product quality across different production scales. By focusing on improving cell viability and functionality, CellRev’s technology significantly increases yield and productivity, while reducing costs, making it a game-changer for the industry. As the company continues to refine its offerings, it remains committed to solving the inefficiencies that have long plagued cell-based manufacturing processes.

Supporting growth with strategic partnerships

Happiness Capital’s investment in CellRev has been a pivotal factor in the company’s growth and success. When Happiness Capital first invested, CellRev was focused on unlocking scalability in the alternative protein sector. However, as the company evolved, so did its mission—shifting its focus to the biopharmaceutical industry, where the opportunities were more immediate and impactful. Throughout this transition, Happiness Capital has been an unwavering partner, providing not only financial backing but also strategic guidance. This support has allowed CellRev to seize significant commercial opportunities, preparing the company for a major product launch and positioning it at the forefront of the biopharmaceutical industry.

Celebrating milestones on the path to global health

Since its inception, CellRev has achieved several significant milestones, including the commercialization of its first media additive product and the launch of its industry-first bioprocessing platform. The company has secured paid trials with leading pharmaceutical companies across the United States, Germany, the UK, and Japan, demonstrating the global demand for its innovative solutions.

Looking ahead, CellRev is focused on expanding its presence in North America, with plans to establish a local sales office to better serve the U.S. market. By addressing the estimated 500% deficit in manufacturing capacity, CellRev is poised to play a critical role in the future of cell therapy manufacturing, ensuring that life-saving treatments can reach those who need them most.